Inventor · disambiguated record
Bryan C. Barnhart
Also filed as: BARNHART BRYAN · BARNHART BRYAN C · BARNHART BRYAN CRAWFORD
14 granted patents·16 pending applications·88 citations·filing 2010–2024
91Inventor score
Files withBRISTOL MYERS SQUIBB CO26UNIV ROCKEFELLER2ABCELLERA BIOLOGICS INC1BRISTOL MAYERS SQUIBB COMPANY1
Top patents by PatentIndex Score
30 records- 0197US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 0296US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 0393US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 0491US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 0590US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 0688US11524992B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 13, 2022·2 cites·12 claims
- 0787US10479838B2Antibodies to CD40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2016·Granted Nov 19, 2019·7 cites·10 claims
- 0886US11103579B2Combination of DR5 agonist and anti-PD-1 antagonist and methods of useBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 31, 2021·2 cites·14 claims
- 0984US2024336695A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1081US10584160B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 10, 2020·3 cites·22 claims
- 1180US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1278US12492238B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 9, 2025·0 cites·6 claims
- 1378US11306149B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 19, 2022·1 cites·20 claims
- 1474US11952427B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Apr 9, 2024·0 cites·20 claims
- 1574US2024141059A1Antibodies comprising modified heavy constant regionsBRISTOL MAYERS SQUIBB COMPANY·Filed 2023·Application pending·0 cites
- 1672US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 1771US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1870US2022098302A1Combination of dr5 agonist and anti-pd-1 antagonist and methods of useBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1968US2021054091A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2067US10844130B2Nucleic acids encoding an anti-CD40 antibodyBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 24, 2020·0 cites·16 claims
- 2164US2019055320A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 2260US2020268901A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2359US2018142030A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 2457US2016067337A1Combination of dr5 agonist and anti-pd-1 antagonist and methods of useBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 2556US2023140384A1Antibodies to cd40 with enhanced agonist activityBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2655US2020299400A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 2752US2020071412A1Antibodies to cd40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2019·Application pending·0 cites
- 2851US2023295310A1CD3 T-Cell Engagers and Methods of UseABCELLERA BIOLOGICS INC·Filed 2023·Application pending·0 cites
- 2938US2019284293A1Combination therapy with anti-cd73 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3038US2011123545A1Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseasesBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →